The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
MaverickD you can call it what you want I couldn’t care less it’s very subjective of course. Some may be disgruntled the board of a non profit making company has nailed on millions worth of bonus for themselves. I do agree with you on this though it is very positive. That’s the second time I have agreed with one of your posts ha ha.
Balanced.
That was the article I quoted from. Should have put it up but I’m not a night owl and was at the end of my day. It will be interesting to see how the FDA interpret the trial. I guess if the safety profile is good they will conditionally accept the results for use but rerun the trial again, I can’t see them delaying the manufacture for another 6months.
Maybe a president being set. Sound familiar?
Just a thought NL!!
Talking about flawed trials here’s an excerpt from the Astra Zeneca vaccine trial.
“ There was no age breakdown given for the two groups from AstraZeneca when the company reported its results on Monday. The initial half-dose was used in some people because of an error in the quantity of vaccine put into some vials, Slaoui said.”
Now you wouldn’t have thought that would happen!! Big decision to be made from FDA.
If AZ get this passed Lupuzor will fly through.
Yes that thought has floated up before on this board. It does seem more likely to fit into this puzzle now. Albeit without any corroborative evidence.
Best not to mention it to anyone though I’m thinking. The ramping posts will go through the roof on a COVID link rumour!!
Dallo.
Yes Avion must be quite confident to take this on. Would love to take a look at their dd.
I can remember Tim calling the data being pulled from P3 ashes was proving very interesting with a bio marker being unearthed. Just a tickle with no details. Nothing released due to negotiations ongoing....
Maybe Tim really has a handful of aces and is prepping the ground for a truly mind boggling turnaround from the FDA!!
Surely Avion wouldn’t touch a company with Imms history unless they thought they were onto a winner? Due diligence carried out and deal struck.
Or maybe he is playing games again.
The volume has improved this last week and that’s a good sign.
Good post Dallo!!
This is speculation on my part BUT.....a contibuting factor to the US trial results may have been the drugs being taken by the US subjects to treat flare ups being very powerfull and taken as randomly as the flare ups occur. There was no control or record made of continuing medicines being used on the trial. Theres since being quite a bit of literature being put out by the US Lupus Foundation regards smaller, more optomised trial designs.
Its pointing in the right direction i believe.(at last?)
A takeover!!! Hope not that would be a cop out at this stage.
May be that the US internal politics have delayed things a bit. Hopefully the potential suitors can financially plan better now for the next 4 years now?
Not sure if the title to this post is an exclamation of hope or a valid point. I do remember way back in the P3 aftermath ashes, talk of in the data collected a useful biomarker useful for highlighting a subset of patients who respond well to Lupuzor. This might be the cause of the application of conditional approval. Exciting if it is I’d say.
Hope Avion do a better job of the P3 this time!!